Based on the strong performance of the Bioprocess Solutions Division in the first half of 2020 as well as on high demand also expected to continue for the rest of the current fiscal year, Sartorius raised its full-year sales and earnings guidance for this division and thus for the entire Gr ... more
Sartorius closes acquisition of selected assets of Danaher Life Sciences
Broadens portfolio for the development and production of biotech medicines
Sartorius successfully closed the acquisition of selected life science businesses of Danaher Corporation. The transaction was completed on April 30, 2020, after receiving the required regulatory approvals.
“The acquisition of this portfolio is a further milestone for Sartorius. The assets we purchased are an excellent strategic and operational fit with both our divisions. We are very pleased to welcome approximately 300 new Sartorius employees and to combine our expertise to become even more relevant together for our biopharma and life science customers,” said Sartorius Executive Board Chairman and CEO Dr. Joachim Kreuzburg. Sartorius paid a purchase price of 825 million U.S. dollars for the acquisition and, upon execution of the purchase agreement on October 19, 2019, has been preparing for integration of the acquired businesses into the two divisions of the Sartorius Group. Despite the special conditions prevailing during the pandemic crisis, integration can therefore be initiated immediately following the closing.
The businesses acquired by Sartorius generated revenue of approximately 170 million U.S. dollars in 2019 and cover various laboratory and bioprocessing technologies, which are complementary to the portfolio lineups of both Sartorius divisions. The company’s broader offering as a result of the acquisition will support customers even more comprehensively in the development of biotech medicines and vaccines, as well as in the safe and efficient production of such pharmaceuticals. Sartorius is thus extending its market position in bioanalytics as well as in key areas of the manufacture of biotech medications.
The FortéBio business for label-free biomolecular characterization includes innovative protein analysis instruments, biosensors and reagents that are used in drug discovery and will be integrated into the Bioanalytics unit within the Sartorius Lab Products & Services Division. The products are based on patented biolayer interferometry technology and perform real-time analysis of various biomolecular interactions. FortéBio employs approximately 200 people worldwide, has production sites in Fremont, California, USA, and Shanghai, China, and accounts for close to half of the revenue generated by the acquired businesses.
With the chromatography systems and resins business also acquired, Sartorius is expanding the portfolio of its Bioprocess Solutions Division in the downstream processing area. This business addresses an essential step in the purification of biopharmaceuticals and encompasses both reusable and single-use equipment, columns and resins. Furthermore selected product groups in the areas of stainless steel hollow fiber and single-use technology tangential flow filtration systems and single-use flow kits will additionally strengthen the division’s portfolio lineup in downstream processing. A further asset to be allocated to the Bioprocess Solutions Division is the SoloHill business covering microcarrier technology and particle validation standards used in cell cultures and other bioprocesses. Together, these various business entities employ approximately 100 people at their sites in Portsmouth, U.K.; Cergy, France; Ann Arbor, Michigan, USA; and Hopkinton, Massachusetts, USA.
Sartorius started off fiscal 2020 dynamically with significant double-digit growth in order intake, sales revenue and earnings. “We are very satisfied overall with our first-quarter results and confident about our business progress in the further course of the year,” commented CEO Dr. Joach ... more
New brand promise, new logo, new colors – Sartorius looks different now. The company has revised its brand look. At the focus of this relaunch is Sartorius’ new brand promise that it summarizes in its new claim: Simplifying Progress. With its products and technologies, the company aims to s ... more
Key Benefits of the Cubis II include: Customizable modularity Choose from among 45 weighing modules, two modern user interfaces, several draft shields, and more than 60 software application for thousands of different possible configurations Choose from our adaptable, preconfigured software ... more
Sartorius has signed an agreement to acquire parts of Danaher’s Life Science Portfolio for approximately $750 million in cash. The businesses had combined sales turnover of approximately $140 million in 2018 with a strong growth profile and double-Digit profit margins. They employ around 30 ... more
Phenomenex Inc. announced it has signed a definitive agreement to be acquired by Danaher Corporation. Phenomenex will operate as a standalone operating company, retaining the Phenomenex brand, its personnel and site locations. "Phenomenex is a widely recognizable brand that we are proud to ... more
Danaher Corporation announced that it has entered into a definitive merger agreement with Pall Corporation pursuant to which Danaher will acquire all of the outstanding shares of Pall for $127.20 per share in cash, or a total enterprise value of approximately $13.8 billion, including assume ... more
- 1analytica 2020: The world’s leading trade fair extends its reach with analytica virtual
- 2analytica 2020: World’s leading trade fair to be held virtually
- 3Sweat for health: Sensor Patches as Fitness Trackers
- 4Leap forward in the fight against antibiotic resistance
- 5Trust in AI but not blindly
- 6Portable, point-of-care COVID-19 test could bypass the lab
- 7Researchers dramatically downsize technology for fingerprinting drugs and other chemicals
- 8New insights into lung tissue in Covid-19 disease
- 9Electron movements in liquid measured in super-slow motion
- 10New 'molecular computers' find the right cells